First AD

Second AD

Key Takeaways and Clinical Pearls in the Treatment of R/R ALL

Clinical

® Clinical Focus page includes a listing of all specialities covered across  OncLive.com, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, hematologic malignancies, and gynecologic cancers. Each individual specialty page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research.


OncLive Peer Exchange® 

® Peer Exchange video program comprises lively expert panel discussions feature peer-to-peer exchanges providing authoritative insights, opinions, and perspectives on important issues facing today’s health care professionals. Episodes focus on updates and insights across solid and hematologic malignancies, including breast cancer, lung cancer, gastrointestinal cancers, genitourinary cancers, gynecological cancers, and hematologic malignancies. 

Video Series

Expert Perspectives & Insights into CAR T-cell Therapy in Relapsed / Refractory Acute Lymphoblastic Leukemia  

Peer Exchange

The key opinion leaders provide concluding insights and essential recommendations regarding the management of relapsed/refractory acute lymphoblastic leukemia.

Overview of CAR T-cell Therapies in R/R B-cell ALL 

CAR T-cell Therapy: Mechanisms of Actions of Brexucabtagene Autoleucel and Obecabtagene Autoleucel

Considerations for Dosing and Lymphodepletion with CAR T-cell Therapy in R/R ALL

Expert Perspectives on CAR T-Cell Therapy Logistics: Collection to Treatment  

Overview of Available Treatment Options in R/R B-cell ALL

Navigating CAR T-cell Therapy in R/R ALL: Expert Perspectives

Expert Insights on ZUMA-3 Data Updates: 4-Year Follow-up and Real World Data

Treatment Considerations and Patient Selection for CAR T-cell Therapy in R/R ALL

Expert Perspectives on Bridging Therapy Strategies Prior to CAR T-cell Therapy

Sequencing Strategies with CAR T-cell Therapy in Patients with or without Prior Blinatumomab Treatment

Translating Data Updates from FELIX and ZUMA-3 to the Clinical Practice Setting

Expert Perspectives on the Potential Impact of Obe-cel on the Treatment Landscape for R/R ALL

Treatment Approaches with Consolidation and Maintenance Post CAR T-cell Therapy

Future Perspectives on CAR T-cell Therapy in R/R B-cell ALL

Frequency, Correlation with Clinical Outcomes, and Risk Factors for Severe CRS and ICANS in CAR T-cell Therapy

Expert Perspectives in Monitoring and Management Strategies for CRS, ICANS, and Other Long-Term Toxicities Associated with CAR T-cell Therapy

Logistical and Access Challenges with CAR T-cell Therapy in R/R ALL

Strategies and Resources for Overcoming Barriers to CAR T-Cell Therapy

Role of Multidisciplinary Team & Logistics of  CAR T-cell Therapy Administration in the Inpatient or Outpatient Setting